Oncolytic viruses for induction of anti-tumor immunity - PubMed (original) (raw)
Review
Oncolytic viruses for induction of anti-tumor immunity
Alex W Tong et al. Curr Pharm Biotechnol. 2012 Jul.
Abstract
Oncolytic virotherapy is an evolving but, as yet, unrealized treatment option for cancer. This approach harnesses the cancer-restricted replicative activity of engineered viruses to achieve tumor cell kill. Tumors that are resistant to chemotherapy or radiotherapy can be susceptible to viral oncolysis because of distinct cell kill mechanisms. There is now compelling evidence that collateral induction of anti-tumor immune responses contributes substantially to viral antitumor activities. In addition to the expected anti-viral immune clearance, the "danger" signal created by virus-infected cells can generate immune co-stimulation known to override immune suppression and reverse tolerance within the tumor microenvironment. Our recent findings indicate that immune activation augments the clinical outcomes of oncolytic virotherapy. Strikingly similar and robust clinical response rates ( > 25%) were observed among advanced cancer patients following intratumoral treatments with adenoviral (AdΔ24) and herpes simplex (JS1/34.5-/47) constructs armed with an integrated granulocyte-macrophage colony-stimulating factor (GMCSF) payload. Both agents produced regressions in injected as well as distant, uninjected lesions, demonstrating systemic effectiveness. We discuss the innate and adaptive immune activating events that may contribute to these clinical outcomes, and examine systemic delivery strategies to tilt the immunological balance from viral clearance to tumor elimination.
Similar articles
- Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G. Grossardt C, et al. Hum Gene Ther. 2013 Jul;24(7):644-54. doi: 10.1089/hum.2012.205. Hum Gene Ther. 2013. PMID: 23642239 Free PMC article. - Multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer.
Paiva LR, Silva HS, Ferreira SC, Martins ML. Paiva LR, et al. Phys Biol. 2013 Apr;10(2):025005. doi: 10.1088/1478-3975/10/2/025005. Epub 2013 Mar 15. Phys Biol. 2013. PMID: 23492870 - Integrating oncolytic viruses in combination cancer immunotherapy.
Bommareddy PK, Shettigar M, Kaufman HL. Bommareddy PK, et al. Nat Rev Immunol. 2018 Aug;18(8):498-513. doi: 10.1038/s41577-018-0014-6. Nat Rev Immunol. 2018. PMID: 29743717 Review. - Evolution of oncolytic viruses: novel strategies for cancer treatment.
Atherton MJ, Lichty BD. Atherton MJ, et al. Immunotherapy. 2013 Nov;5(11):1191-206. doi: 10.2217/imt.13.123. Immunotherapy. 2013. PMID: 24188674 Review. - Potentiating oncolytic viral therapy through an understanding of the initial immune responses to oncolytic viral infection.
Alvarez-Breckenridge CA, Choi BD, Suryadevara CM, Chiocca EA. Alvarez-Breckenridge CA, et al. Curr Opin Virol. 2015 Aug;13:25-32. doi: 10.1016/j.coviro.2015.03.015. Epub 2015 Apr 4. Curr Opin Virol. 2015. PMID: 25846988 Review.
Cited by
- Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions.
Wang M, Wang X, Jin X, Zhou J, Zhang Y, Yang Y, Liu Y, Zhang J. Wang M, et al. Front Immunol. 2023 May 25;14:1175118. doi: 10.3389/fimmu.2023.1175118. eCollection 2023. Front Immunol. 2023. PMID: 37304305 Free PMC article. Review. - Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages.
Dong H, Li M, Yang C, Wei W, He X, Cheng G, Wang S. Dong H, et al. Cancer Cell Int. 2023 Jan 5;23(1):1. doi: 10.1186/s12935-022-02846-x. Cancer Cell Int. 2023. PMID: 36604694 Free PMC article. Review. - Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer.
Yang K, Feng S, Luo Z. Yang K, et al. Biomedicines. 2022 Dec 15;10(12):3262. doi: 10.3390/biomedicines10123262. Biomedicines. 2022. PMID: 36552019 Free PMC article. Review. - Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective.
Garmaroudi GA, Karimi F, Naeini LG, Kokabian P, Givtaj N. Garmaroudi GA, et al. Oxid Med Cell Longev. 2022 Jul 22;2022:3142306. doi: 10.1155/2022/3142306. eCollection 2022. Oxid Med Cell Longev. 2022. PMID: 35910836 Free PMC article. Review. - Neospora caninum: a new class of biopharmaceuticals in the therapeutic arsenal against cancer.
Lantier L, Poupée-Beaugé A, di Tommaso A, Ducournau C, Epardaud M, Lakhrif Z, Germon S, Debierre-Grockiego F, Mévélec MN, Battistoni A, Coënon L, Deluce-Kakwata-Nkor N, Velge-Roussel F, Beauvillain C, Baranek T, Lee GS, Kervarrec T, Touzé A, Moiré N, Dimier-Poisson I. Lantier L, et al. J Immunother Cancer. 2020 Nov;8(2):e001242. doi: 10.1136/jitc-2020-001242. J Immunother Cancer. 2020. PMID: 33257408 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources